<DOC>
	<DOCNO>NCT02278120</DOCNO>
	<brief_summary>This multi-center , randomize , double-blinded , placebo control trial pre-menopausal woman advance breast cancer .</brief_summary>
	<brief_title>Study Efficacy Safety Premenopausal Women With Hormone Receptor Positive , HER2-negative Advanced Breast Cancer</brief_title>
	<detailed_description>The purpose study assess efficacy LEE011 , measure progression free survival ( PFS ) , premenopausal woman HR positive , HER2 negative advance breast cancer</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Patient advance ( locoregionally recurrent metastatic ) breast cancer amenable curative therapy Patient premenopausal perimenopausal time study entry Patients receive ( neo ) adjuvant therapy breast cancer eligible Patient histologically and/or cytologically confirm diagnosis estrogenreceptor positive and/or progesterone receptor positive breast cancer Patient HER2negative breast cancer Patient must either measurable disease If measurable disease present , least one predominantly lytic bone lesion Patient Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Patient adequate bone marrow organ function Patient receive prior CDK4/6 inhibitor Patient postmenopausal Patients currently inflammatory breast cancer screen . Patients receive prior hormonal anticancer therapy advance breast cancer , except ≤ 14 day tamoxifen NSAI ± goserelin advance breast cancer prior randomization . Patient concurrent malignancy malignancy within 3 year randomization , exception adequately treat basal cell skin carcinoma , squamous cell skin carcinoma , nonmelanomatous skin cancer curatively resect cervical cancer . Patient CNS metastasis . Patient active cardiac disease history cardiac dysfunction Patient currently use antineoplastic agent Patient pregnant nursing physiologically capable become pregnant use highly effective contraception</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>HR-positive</keyword>
	<keyword>HER2-negative</keyword>
	<keyword>Advanced breast cancer</keyword>
	<keyword>Letrozole</keyword>
	<keyword>Anastrozole</keyword>
	<keyword>Tamoxifen</keyword>
	<keyword>Goserelin</keyword>
	<keyword>CDK</keyword>
	<keyword>CDK4</keyword>
	<keyword>CDK6</keyword>
	<keyword>CDK4/6</keyword>
	<keyword>Phase III</keyword>
	<keyword>ER-positive</keyword>
	<keyword>PR-positive</keyword>
	<keyword>Premenopausal</keyword>
</DOC>